R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial (Q64655089)
Jump to navigation
Jump to search
clinical trial
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial |
clinical trial |
Statements
Study Phase II Non-randomized Prospective Open to Assess the Combination of Rituximab, Bendamustine, Mitoxantrone, Dexamethasone (R-BMD) in Patients With Follicular Lymphoma Refractory or Relapsed (English)
0 references
July 2009
0 references
December 2013
0 references
61
0 references
18 year
0 references
75 year
0 references